Cerus Corp. (CERS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.59+0.78%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Cerus aims to grow revenue to about $229 million in 2026. The company plans a share buyback program. Net losses are improving, down from -$2.18M to -$1.64M in early 2026. Management focuses on better cash flow from operations.
Cerus still loses money and cash flow is negative. Revenue growth is slow. Buyback and M&A plans face setbacks. The company may not reach profit soon.
The price is about 2% above our fair value near $3.23. The market expects very low growth and continued losses.
Breaks if: No buyback program announced or executed by end of 2026
Breaks if: Cash flow falls below -$3.05M
Net income worsens below -$2.18M
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CERS represents a growth-oriented investment with a focus on expanding product revenue and regulatory approvals. The current thesis state is intact, but the company faces elevated risks and mixed recent performance.
The market appears to have a low expectations gap, suggesting that current valuations are justified based on the company's performance and growth prospects. CERS is priced at a premium compared to its peers, reflecting some confidence in its long-term strategy.
Management is on track to meet its revenue growth targets, with product revenue showing consistent growth. However, the company remains loss-making, and near-term risks include a potential miss in earnings due to its smaller-cap status.
The long-term thesis hinges on the company's ability to maintain growth in product revenue and successfully advance regulatory approvals. Additionally, broader sector performance and economic conditions will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $203 million in FY26
Over the next 1 to 3 years, CERS will need to navigate both internal execution and external market conditions to sustain its growth trajectory. Not investment advice.